Gmax Biopharm
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma company developing both biosimilars and novel biologics for oncology and immunology.
OncologyImmunology
Technology Platform
An integrated platform for the development and GMP manufacturing of monoclonal antibodies and other therapeutic proteins.
Opportunities
Leveraging biosimilar revenue and manufacturing expertise to de-risk and fund a novel biologics pipeline.
Risk Factors
Margin erosion in the biosimilar business and the high risk of failure for novel drug development.
Competitive Landscape
Faces intense competition in the biosimilar market from large generic pharma companies, while its novel pipeline enters crowded therapeutic areas.